AGIO logo

Agios Pharmaceuticals Inc. (AGIO)

$30.15

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on AGIO

Market cap

$1.80B

EPS

-6.33

P/E ratio

--

Price to sales

19.31

Dividend yield

--

Beta

0.654651

Price on AGIO

Previous close

$31.59

Today's open

$31.29

Day's range

$30.10 - $31.70

52 week range

$22.24 - $46

Profile about AGIO

CEO

Brian Goff

Employees

540

Headquarters

Cambridge, MA

Exchange

Nasdaq Global Select

Shares outstanding

59809651

Issue type

Common Stock

AGIO industries and sectors

Healthcare

Biotechnology & Life Sciences

News on AGIO

Agios Pharmaceuticals, Inc. (AGIO) Q3 2026 Earnings Call Transcript

Agios Pharmaceuticals, Inc. ( AGIO ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Morgan Sanford - Vice President of Investor Relations Brian Goff - CEO & Director Cecilia Jones - Chief Financial Officer Tsveta Milanova - Chief Commercial Officer Sarah Gheuens - Chief Medical Officer and Head of Research & Development Conference Call Participants Alec Stranahan - BofA Securities, Research Division Samantha Semenkow - Citigroup Inc., Research Division Eric Schmidt - Cantor Fitzgerald & Co., Research Division Anish Nikhanj - Truist Securities, Inc., Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Joseph Thome - TD Cowen, Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Luca Issi - RBC Capital Markets, Research Division Presentation Operator Good morning, and welcome to Agios Pharmaceuticals Third Quarter 2026 Conference Call.

news source

Seeking Alpha • Nov 7, 2026

news preview

What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call

Agios Pharmaceuticals NASDAQ: AGIO reported record third-quarter product revenue as its thalassemia drug AQVESME continued its U.S. launch, while the company prepares for a delayed regulatory decision on the drug's use in sickle cell disease.

news source

MarketBeat • Nov 5, 2026

news preview

Agios Reports Third Quarter 2026 Financial Results and Provides Business Update

Mitapivat (PYRUKYND® and AQVESME®) delivered worldwide net revenues of $55.4 million in third quarter of 2026, more than four times the $12.9 million reported in third quarter of 2025 Strong U.S. demand for AQVESME in thalassemia continues, with 619 cumulative prescriptions with completed start forms from REMS-certified physicians, plus 48 additional prescriptions with start forms in process as of September 30, 2026 New PDUFA goal date for mitapivat sickle cell disease sNDA set for February 1, 2027; company is launch-ready and in labeling discussions with FDA 14 abstracts accepted at ASH 2026, including new clinical data for mitapivat in sickle cell disease and for AG-236 in polycythemia vera, highlighting the breadth and depth of Agios' rare hematology portfolio $907.0 million in cash, cash equivalents, and marketable securities as of September 30, 2026, fully funding commercial launches and pipeline programs; company is targeting non-GAAP profitability in 2028 CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the third quarter ended September 30, 2026.

news source

GlobeNewsWire • Nov 5, 2026

news preview

Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to a loss of $1.78 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026

Agios announces new clinical data across company's rare hematology portfolio that will be featured in oral and poster presentations during ASH 2026.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA

FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell disease FDA classified Agios' response to the information request as a major amendment to the mitapivat sNDA, resulting in a three-month review extension Mitapivat sNDA was submitted under the FDA's accelerated approval pathway and granted Priority Review, with an original PDUFA goal date of November 1, 2026 Agios will continue its labeling discussions with the FDA as part of the ongoing sNDA review, including elements of a potential REMS CAMBRIDGE, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease.

news source

GlobeNewsWire • Oct 30, 2026

news preview

Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade)

Agios Pharmaceuticals stock fell >15% after the FDA extended the mitapivat sNDA PDUFA date for sickle cell disease to February 2027. Mitapivat's efficacy in SCD is mixed—endpoint for pain crises not met, but strong reductions in transfusion burden demonstrated. The FDA's delay centers on safety and REMS considerations, not efficacy; no new hepatocellular injury cases were reported in updated safety data.

news source

Seeking Alpha • Oct 30, 2026

news preview

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 29, 2026

news preview

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, November 5, 2026, at 8:00 a.m.

news source

GlobeNewsWire • Oct 8, 2026

news preview

AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know

Agios faces a narrower growth path as tebapivat setbacks shift focus to mitapivat sales, SCD expansion and regulatory prospects.

news source

Zacks Investment Research • Oct 6, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Agios Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Agios Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in AGIO on M1